Processing the protocol with id 132
##########################################
Searching for the item "2a Scientific background and explanation of rationale..."
This part was defined, probably, at this section: 2 BACKGROUND 
I have not found anything about the rationales from titles, lets take a look for the introduction
Rationales: NOT FOUND
For more information about the previous studies, go to sections:
2.4.3 Preclinical Studies with ABI 007 
2.4.4 Clinical Studies with ABI 007 
##########################################
Searching for the item "2b Specific objectives or hypotheses"...
This part was defined, probably, at this section: 1 OBJECTIVES AND ENDPOINTS 
For more information about the primary objectives, go to sections:
1.2.1 Primary Efficacy Endpoint(s) 
For more information about the secondary objectives, go to sections:
1.1.2 Secondary Objective(s) 
1.2.2 Secondary Efficacy Endpoint(s) 
Objectives: FOUND
Occurrences in the text:
3892	evaluate 	"... s to evaluate the efficacy of the combination of ABI 007  and gemcitabine versus gemcitabine alone in..."
4551	determine 	"...  and determine its possible correlation with efficacy outcomes.    1.2 Study Endpoints   1.2.1 Primary..."
##########################################
Searching for the item "3a Description of trial design (such as parallel, factorial) including allocation ratio"...
This part was defined, probably, at this section: 4 STUDY DESIGN AND PLAN 
I found the following features of the study:
5 per arm
Phase III
open label
randomized
2 Gemcitabine Premedication  Initial antiemetic prophylaxis for both arm
multi center
Placebo: NOT FOUND -> active-controlled study?
Allocation ratio: 1:1
##########################################
Checking for the item "4a Eligibility criteria for participants..."
This part was defined, probably, at this section: 3 STUDY POPULATION 
I have found: exclusion criteria, inclusion criteria
##########################################
Checking for the item "5 Interventions for each group with sufficient details to allow replication, including how and when they were actually administered"
This part was defined, probably, at this section: 5.1.2 Study Medication Administration 
##########################################
Checking for the item “7a how sample size was determined”...
This part was defined, probably, at this section: 8.1 Study Design and Sample Size 
##########################################
Searching any information about a randomzation
This part was defined, probably, at this section: 6.5 Randomization and Treatment Phase Evaluations 
Maybe this information will be interesting:
25270	will be randomized	"... Prescribing Information is provided in the Study Manual).  2.5 Proposed Treatment Regimen  Patients will be randomized to one of the following treatment regimens:   ABI 007 125 mg/m2 administered in..."
30999	will be randomized	"... iagnosed with metastatic adenocarcinoma of the pancreas. Six hundred thirty  patients (315 per arm) will be randomized to each treatment regimen in a 1:1 ratio.  The study will consist of the..."
31248	will be randomized	"...    Baseline Assessments: To be performed within 28 days of randomization.   Randomization: Patients will be randomized within 28 days of starting their Baseline  assessments. To ensure that on study..."
72525	will be randomized	"... t be completed within 28 days of randomization. Following  completion of Baseline testing, patients will be randomized. Patients should return within 7  days to begin Cycle 1 of study drug dosing...."
##########################################
Checking for the item “11a  if done, who was blinded after assignment to interventions (eg, participants, care providers, those assessing outcomes) and how.”
Unfortunately, I could not find this part, maybe, due to bad conversion to txt file!
##########################################
Checking for the item “12a  statistical methods used to compare groups for primary and secondary outcomes”
This part was defined, probably, at this section: 8 STATISTICAL METHODS 
I found the following methods:
115137 	 log rank 	 "... es will be tested  using the stratified log rank test. In the event that a..."
117864 	 log rank 	 "... es will be tested using the  stratified log rank test.  8.3.8 Other Secondary..."
121447 	 log rank 	 "...  in the curves will be tested using the log rank test.  Confidential    Page 59..."
116598 	 chi square 	 "... ween the arms will be tested  using the chi square test.  8.3.7.2 Progression..."
119878 	 chi square 	 "... umor response will be  evaluated by the chi square test based on the patient s..."
120407 	  cox  	 "...  overall survival will be evaluated by a Cox regression model.  8.3.8.8 SPARC..."
120989 	  cox  	 "... ll survival (and PFS) with biomarkers, a Cox regression analysis will be  used..."
120085 	 cochran mantel haenszel 	 "... response rates will be tested using the Cochran Mantel Haenszel (CMH) test..."
114431 	 kaplan meier 	 "... l survival which will be analyzed using Kaplan Meier  methods. Survival will be..."
114996 	 kaplan meier 	 "... he hazard ratio (including 95% CI). The Kaplan Meier curve for  survival will..."
116790 	 kaplan meier 	 "... ponse guidelines will be analyzed using Kaplan Meier methods. PFS will be ..."
117728 	 kaplan meier 	 "... he hazard ratio (including 95% CI). The Kaplan Meier curve for PFS will be ..."
118429 	 kaplan meier 	 "... ccurs first. TTF will be analyzed using Kaplan Meier methods.  8.3.8.3 Time to..."
121301 	 kaplan meier 	 "... ratio. For each treatment regimen,  the Kaplan Meier curve for survival will be..."
124583 	 kaplan meier 	 "... time to recovery will be analyzed using Kaplan Meier  methods.  Abraxis..."
